22 hours Ago By ABMN Staff
AllGen Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson ( NYSE:JNJ – Free Report ) by 14.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The firm owned 36,088 shares of the company’s stock after acquiring an additional 4,443 shares during the quarter. Johnson & Johnson accounts for about 2.0% of AllGen Financial Advisors Inc.
’s portfolio, making the stock its 13th largest position. AllGen Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $5,275,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Citizens & Northern Corp boosted its stake in shares of Johnson & Johnson by 3.5% in the 2nd quarter.
Citizens & Northern Corp now owns 1,884 shares of the company’s stock valued at $275,000 after buying an additional 63 shares during the period. Carolinas Wealth Consulting LLC grew its holdings in Johnson & Johnson by 0.4% during the 4th quarter.
Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock worth $2,643,000 after acquiring an additional 64 shares in the last quarter. Epic Trust Investment Advisors LLC increased its position in shares of Johnson & Johnson by 3.6% in the 2nd quarter.
Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after purchasing an additional 64 shares during the last quarter. Pine Harbor Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.9% in the 2nd quarter.
Pine Harbor Wealth Management LLC now owns 3,472 shares of the company’s stock valued at $507,000 after purchasing an additional 64 shares in the last quarter. Finally, Outfitter Financial LLC lifted its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter.
Outfitter Financial LLC now owns 16,632 shares of the company’s stock worth $2,431,000 after purchasing an additional 65 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance Shares of NYSE:JNJ opened at $166.17 on Thursday. The company has a debt-to-equity ratio of 0.
44, a quick ratio of 0.85 and a current ratio of 1.07.
Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.
The company has a 50-day simple moving average of $160.71 and a 200-day simple moving average of $154.09.
The stock has a market capitalization of $399.92 billion, a price-to-earnings ratio of 10.36, a PEG ratio of 2.
71 and a beta of 0.53. Johnson & Johnson Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th.
Shareholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th.
This represents a $4.96 dividend on an annualized basis and a yield of 2.98%.
Johnson & Johnson’s payout ratio is currently 30.92%. Insider Transactions at Johnson & Johnson In other news, VP Robert J.
Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.
10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38.
The sale was disclosed in a document filed with the SEC, which is available at this hyperlink . Company insiders own 0.16% of the company’s stock.
Analysts Set New Price Targets Several research firms recently commented on JNJ. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.
00 to $150.00 in a research report on Tuesday, July 23rd. StockNews.
com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th.
Finally, The Goldman Sachs Group reduced their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th.
Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.
View Our Latest Report on JNJ Johnson & Johnson Profile ( Free Report ) Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Further Reading Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ). Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter .
.
